The FDA clears the first blood test for diagnosing Alzheimer’s disease

There is a new way for the early detection of Alzheimer’s disease. Food and Drug Department (FDA) on Friday cleaned the first blood test for disorder. Fujirebio Diagnostics’ Lumipulse measures the ratio of two proteins related to the presence or absence of Alzheimer’s. Patients with screenshots previously limited to more invasive options: Find a pet crawl or spine.

Lumipulse is designed for use with marks of cognitive landing signs in clinical parameters in clinical settings. At least in the present form, it is not something that the general population can ask as a standard choice.

The test works by measuring two proteins: PTAU217 and β-amyloid 1-42. Blood test calculates the rates that link to the build of amyloid boards in the brain. People with Alzheimer’s PTAU217 and lower β-amyloid are high in 1-42.

In a clinical investigation, the test performed better with more negative results than those who are positive. So Reuters report The test will be used to exclude Alzheimer’s first. More than 97 percent of negative results correspond to a negative pet scan or CSF test result. The results for positives were slightly lower: 91.7 percent. Thus, positive results must be confirmed by more advanced diagnostic tests.